 | Up a level |
Colombo, Nicoletta; Biagioli, Elena; Harano, Kenichi; Galli, Francesca; Hudson, Emma; Antill, Yoland; Choi, Chel Hun; Rabaglio, Manuela; Marmé, Frederic; Marth, Christian; Parma, Gabriella; Fariñas-Madrid, Lorena; Nishio, Shin; Allan, Karen; Lee, Yeh Chen; Piovano, Elisa; Pardo, Beatriz; Nakagawa, Satoshi; McQueen, John; Zamagni, Claudio; ... (2024). Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology, 25(9), pp. 1135-1146. Elsevier 10.1016/S1470-2045(24)00334-6
Colleoni, Marco; Luo, Weixiu; Karlsson, Per; Chirgwin, Jacquie; Aebi, Stefan; Jerusalem, Guy; Neven, Patrick; Hitre, Erika; Graas, Marie-Pascale; Simoncini, Edda; Kamby, Claus; Thompson, Alastair; Loibl, Sibylle; Gavilá, Joaquín; Kuroi, Katsumasa; Marth, Christian; Müller, Bettina; O'Reilly, Seamus; Di Lauro, Vincenzo; Gombos, Andrea; ... (2018). Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet oncology, 19(1), pp. 127-138. Elsevier 10.1016/S1470-2045(17)30715-5
